If you have spent any time reading about longevity science, you have run into NAD+. It is the coenzyme at the center of cellular energy production, DNA repair, and the enzymatic pathways most associated with healthy aging. You may also have run into the alphabet soup that surrounds it: NAD+, NR, NMN, NADH. These are not interchangeable. They are related molecules at different points in the same metabolic pathway, and understanding the difference is the key to understanding what any given NAD+ product actually does.

Niagen is the brand name for nicotinamide riboside, usually abbreviated NR. It is a precursor to NAD+, which means it is a building block the body converts into NAD+ rather than NAD+ itself. NR has become one of the most extensively studied compounds in the entire NAD+ field, with more than 45 clinical studies examining its safety and its ability to raise NAD+ levels in humans.

This article is about the science of nicotinamide riboside: how it works, what the human trials actually demonstrate, where the evidence is strong and where it is still emerging, and how a precursor like NR differs from a direct NAD+ injection. It is not a sales pitch. The NAD+ field has a marketing problem, and the most useful thing this article can do is separate what is genuinely established from what is still being investigated.

The short answer

Nicotinamide riboside (NR), sold under the brand name Niagen, is a form of vitamin B3 that the body converts into NAD+. In human clinical trials, oral NR has been shown to raise blood NAD+ levels in a clear, dose-dependent way, which is the single most well-established fact about the compound. Whether raising NAD+ through NR supplementation produces specific downstream health benefits (cardiovascular, cognitive, metabolic, anti-inflammatory) is an active area of research with promising early human data, but it is not yet settled science, and in May 2026 a U.S. advertising review board ruled that the existing studies do not support definitive "clinically proven" health claims.

NR differs from a direct NAD+ injection in an important way. NR is a precursor that the body has to convert into NAD+. A NAD+ injection delivers the finished molecule. Both approaches aim to raise NAD+ availability; they simply start at different points in the pathway.

NAD+, and why the body runs on it

NAD+ (nicotinamide adenine dinucleotide) is one of the most important molecules in human biology. Nearly every cell uses it. It serves two broad functions.

First, it is central to energy metabolism. NAD+ shuttles electrons in the reactions that convert food into cellular energy (ATP), operating in the mitochondria as a core part of the machinery that keeps cells powered. Without adequate NAD+, energy production falters.

Second, NAD+ is the required fuel for a family of enzymes involved in cellular maintenance and repair, most notably the sirtuins and the PARP enzymes. Sirtuins are involved in regulating cellular stress responses, mitochondrial function, and several pathways associated with healthy aging. PARP enzymes are central to DNA repair. Both consume NAD+ to do their work, which means NAD+ availability directly influences how well cells maintain and repair themselves.

Here is the problem that drives the entire NAD+ field: NAD+ levels decline with age. Research has documented that NAD+ concentrations in human tissue fall substantially across the lifespan. The hypothesis underlying NAD+ science is that restoring NAD+ toward youthful levels might support the cellular functions that depend on it. That hypothesis is plausible, mechanistically well-grounded, and still being tested. It is not yet proven that raising NAD+ reverses or slows aging in humans. It is proven that NAD+ is essential and that it declines. The gap between those two statements is where most of the ongoing research lives.

What nicotinamide riboside actually is

The body cannot efficiently absorb NAD+ as a whole molecule through the digestive tract, which is why NAD+ science has focused heavily on precursors: smaller molecules the body can absorb and then convert into NAD+ through known enzymatic steps.

Nicotinamide riboside is one such precursor. It is a form of vitamin B3, structurally distinct from the other B3 forms (niacin and nicotinamide). NR enters cells and is converted to NAD+ through a short, well-characterized pathway: NR is phosphorylated by enzymes called NRK1 and NRK2 into nicotinamide mononucleotide (NMN), which is then converted into NAD+. This is the so-called salvage pathway, and NR enters it at a point that makes conversion efficient.

NR was first identified as an NAD+ precursor vitamin by researchers led by Dr. Charles Brenner, and the first controlled human clinical trial of NR was published in 2016 in Nature Communications, demonstrating that the compound is safe in humans and raises NAD+. The patented, crystalline form of NR chloride is what is branded as Niagen. It holds Generally Recognized as Safe (GRAS) status with the FDA and has been the subject of New Dietary Ingredient notifications, and is the NR ingredient used in the majority of registered nicotinamide riboside clinical trials.

The science, benefit by benefit

The research on NR is best understood in tiers: what is well-established, what is promising with human data, and what is still primarily mechanistic or preclinical. This article organizes the five most-discussed benefits along that spectrum, and is explicit about which tier each one occupies.

Benefit 1: Raising NAD+ levels (well-established)

This is the one claim about NR that is genuinely robust. Multiple independent randomized controlled trials have demonstrated that NR raises blood NAD+ in a dose-dependent manner.

The clearest dataset comes from a 2019 randomized, double-blind, placebo-controlled trial published in Scientific Reports. In healthy overweight adults, oral NIAGEN raised whole-blood NAD+ by 22% at 100mg, 51% at 300mg, and 142% at 1,000mg, with the increases appearing within two weeks and sustained throughout the eight-week study. Notably, there were no reports of flushing (a common side effect of older B3 forms like niacin) and no significant difference in adverse events between the NR and placebo groups.

A 2018 randomized crossover trial in Nature Communications in healthy middle-aged and older adults independently confirmed that chronic NR supplementation effectively elevates NAD+ and is well-tolerated.

This benefit is not seriously disputed. NR raises NAD+. The interesting and unsettled questions are all about what raising NAD+ then does.

Benefit 2: Cellular energy and mitochondrial function (promising, mechanistically strong)

Because NAD+ is central to mitochondrial energy production, the hypothesis that restoring NAD+ supports cellular energy is mechanistically well-grounded. The human data is supportive but still developing.

A clinical trial assessing high-dose NR (2,000mg/day) found that it nearly doubled whole-blood NAD+ levels and increased mitochondrial respiration in peripheral blood mononuclear cells. Research published in the American Journal of Clinical Nutrition found that NR supplementation (1g/day for six weeks) in overweight or obese men modestly improved body composition and increased metabolic rate during sleep.

These are real findings, but they are early and the effect sizes are modest. "Supports cellular energy production through NAD+-dependent enzyme function" is a defensible mechanistic statement. "Niagen will give you more energy" is a marketing claim the evidence does not yet fully support.

Benefit 3: Cardiovascular function, blood pressure and arterial stiffness (promising, early human data)

The most interesting downstream human evidence for NR is cardiovascular.

A pilot study from the laboratory of Dr. Douglas Seals at the University of Colorado Boulder, published as part of the 2018 Nature Communications trial and expanded in subsequent work, found that six weeks of NR supplementation lowered systolic blood pressure and reduced aortic stiffness (measured as carotid-femoral pulse wave velocity, the gold-standard measure). In the subgroup of participants who started with elevated systolic blood pressure, the reduction in systolic pressure reached approximately 8 mmHg, a clinically meaningful change if confirmed in larger trials.

These findings were promising enough to justify a larger phase IIa randomized controlled trial specifically targeting blood pressure and arterial stiffness in adults with elevated systolic pressure. The mechanism is plausible: NAD+ supports the function of the endothelium (the inner lining of blood vessels) and influences vascular smooth muscle tone, oxidative stress, and inflammation, all of which affect blood pressure and arterial stiffness.

This is promising science. It is not yet established that NR should be used to manage blood pressure, and it is not a substitute for proven antihypertensive therapy. But it is the area where the downstream evidence is strongest.

Benefit 4: Healthy aging through sirtuin and DNA-repair pathways (mechanistically central, outcomes unproven in humans)

This is the benefit most associated with NR in popular longevity discussion, and it is also the one where the gap between mechanism and proven human outcome is widest.

The logic is sound. NAD+ is the required substrate for sirtuins and PARP enzymes. Sirtuins regulate cellular stress responses and mitochondrial biogenesis and have been linked to longevity pathways across multiple species. PARP enzymes repair DNA. As NAD+ declines with age, the activity of these NAD+-dependent enzymes is constrained. Restoring NAD+ should, in theory, support their function.

Much of the strongest evidence for this pathway comes from animal studies, where boosting NAD+ has produced effects on metabolism, nerve function, and lifespan in mice. Translating those findings to humans is exactly the work that is still in progress. Restoring the substrate (NAD+) is proven. Demonstrating that this produces measurable anti-aging outcomes in humans (longer healthspan, slowed biological aging) is not yet done. The trials that would prove it are long, expensive, and difficult to design.

The honest framing: NR restores a molecule that the body's repair and longevity enzymes depend on. Whether that translates into slower aging in humans remains an open and actively researched question.

Benefit 5: Reduced inflammation and cellular stress resilience (emerging)

A growing body of research suggests NR may reduce markers of inflammation. Human studies have reported that NR reduces circulating inflammatory cytokines in older adults. A phase I clinical trial in Parkinson's disease patients found NR supplementation was associated with reduced inflammatory cytokine levels in both serum and cerebrospinal fluid, alongside upregulation of pathways associated with mitochondrial and proteasomal function.

A 2025 randomized controlled trial published in eClinicalMedicine examined NR (2,000mg/day) for cognition and symptom recovery in long-COVID, on the rationale that NR may reduce neuroinflammation and support mitochondrial function. This represents the kind of targeted clinical research now being done to test NR's downstream effects in specific conditions.

This benefit is emerging. The mechanism is plausible, the early human signals are interesting, and the research is ongoing.

NR versus NMN: the precursor debate

If you have researched NAD+ supplements, you have encountered NMN (nicotinamide mononucleotide), the other major NAD+ precursor. NR and NMN are closely related: in the salvage pathway, NR is actually converted into NMN as an intermediate step on the way to NAD+.

The two have been the subject of genuine scientific and commercial rivalry. The most relevant recent data comes from a 2026 head-to-head study published in iScience, a Cell Press journal, which compared NR and NMN in the same human participants at the same 1,200mg dose under the same conditions. It found that NR raised blood NAD+ by 161% after eight days, compared with 67% for NMN. This is the cleanest direct comparison available, and it favors NR for raising blood NAD+.

There is also a regulatory dimension. NMN's status as a legal dietary supplement ingredient has been contested: the FDA excluded it in 2022, then reversed that decision in 2025. NR (Niagen) has held stable GRAS status throughout. For a fuller treatment of this comparison, see CLYR's companion article on NAD+ versus NMN versus NR in the Journal.

How a precursor differs from a direct NAD+ injection

This is the distinction that matters most for understanding where injectable Niagen fits.

A direct NAD+ injection delivers the finished NAD+ molecule into the body. The body does not need to convert anything; the molecule is already in its active form.

Niagen (nicotinamide riboside) is a precursor. It delivers a building block that the body's own enzymes convert into NAD+ through the salvage pathway. The conversion is efficient and well-characterized, but it is an extra step.

Why would anyone choose a precursor over the finished molecule? A few reasons are proposed. Precursors may be gentler and produce a smoother rise in NAD+ rather than a sharp spike. They engage the body's natural regulatory machinery, which may modulate how much NAD+ is ultimately produced. And the body may distribute precursor-derived NAD+ differently than directly administered NAD+. Conversely, advocates of direct NAD+ administration argue that delivering the finished molecule bypasses any bottleneck in the conversion pathway.

An important and honest caveat about delivery route: essentially all of the published clinical research on nicotinamide riboside studied oral NR. Injectable NR (the form compounded by pharmacies such as Olympia Pharmaceuticals and offered through CLYR) has not been the subject of the same body of published trials. The scientific rationale for an injectable route is that it bypasses the digestive tract entirely, which avoids the absorption and first-pass metabolism limitations that constrain oral NAD+ precursors, plausibly delivering more of the compound into systemic circulation. That rationale is mechanistically reasonable, but it should be understood as a rationale rather than a proven claim, because the head-to-head trials comparing injectable to oral NR have not been published.

Who Niagen is sourced from

The injectable Niagen offered through CLYR is compounded by Olympia Pharmaceuticals, a state-licensed 503A and 503B compounding pharmacy that is LegitScript certified and accredited by the National Association of Boards of Pharmacy. The product uses the patented Niagen nicotinamide riboside ingredient. As with all compounded medications, the finished injectable product is not FDA-approved, and compounded products are not reviewed by the FDA for safety, efficacy, or quality before reaching patients.

Safety, precautions, and contraindications

Nicotinamide riboside has a favorable safety profile in the oral clinical trials conducted to date, with adverse event rates generally comparable to placebo and notably without the flushing associated with niacin. That said, the injectable route and the specific patient context matter, and several precautions apply.

Per the prescribing guidance for injectable Niagen, this medication should be avoided by individuals who:

And used with caution by individuals who:

The cancer precaution deserves a direct explanation rather than a footnote. NAD+ is used by all rapidly dividing cells, including cancer cells, and there is legitimate scientific discussion about whether raising NAD+ availability could theoretically support the metabolism of an existing cancer. This is why the cancer-history exclusion exists. It is a precautionary position grounded in real biological reasoning, and it is one of the clearest examples of why NAD+ precursor therapy should be undertaken only under the supervision of a licensed clinician who knows your full medical history.

The regulatory picture, stated plainly

In May 2026, the National Advertising Review Board (a part of BBB National Programs) ruled that the clinical studies relied upon by Niagen Bioscience did not support certain "clinically proven" claims tied to heart health, brain health, immune support, anti-aging, and energy benefits, and recommended those claims be discontinued or modified. Niagen Bioscience has stated it intends to appeal.

What this means for a reader trying to make an informed decision: the evidence that NR raises NAD+ is strong. The evidence that raising NAD+ via NR produces specific health outcomes is, in the judgment of this advertising review board, not yet strong enough to support definitive "clinically proven" claims. Both of those things are true at the same time. A responsible presentation of NR acknowledges the proven mechanism and the unproven outcomes, and does not blur the line between them. That is the standard this article has tried to hold to.

The Bottom Line

Nicotinamide riboside is one of the most thoroughly studied NAD+ precursors in human research, and the core finding is solid: it raises NAD+ levels safely and dose-dependently. The downstream benefits that NAD+ science is ultimately interested in (cardiovascular function, cellular energy, healthy aging, reduced inflammation) are supported by promising but still-developing human evidence, and the regulatory bodies have been clear that the science does not yet justify definitive health claims. The most honest thing anyone can say about NR is that it does something real and measurable to a molecule that matters enormously, and that the rest of the story is still being written.

Injectable Niagen is a delivery approach designed to bypass the absorption limits of oral supplements. The molecule's NAD+-raising effect is well-supported by oral research; the injectable route is a mechanistically reasonable extension that has not yet been studied to the same degree.

If you are interested in NAD+ support, CLYR offers both injectable Niagen (the NR precursor) and direct NAD+ injections, prescribed by licensed clinicians after a complete medical review. To understand how the precursor approach compares to direct NAD+ administration, see our companion field guide on NAD+, or join the Niagen waitlist when available.

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Injectable Niagen is a compounded medication; compounded products are not approved by the FDA, which means the FDA does not review these products for safety, efficacy, or quality before they reach patients. This article is for educational purposes only and does not constitute medical advice. Nicotinamide riboside should not be used by individuals with active or prior cancer, during pregnancy or breastfeeding, or by individuals with rheumatoid arthritis, and should be used with caution by individuals taking diabetes medications or blood thinners. The decision to begin any prescription or compounded medication should be made in consultation with a licensed healthcare provider who knows your full medical history. Individual results vary.